Bispecific antibodies combine two therapeutic antibodies ... affinity of the heavy chain–light chain variable domains (VH–VL) to induce heterodimerization of the heavy chains.

The antibody molecule in particular has ... and 1AQK (MUC1) for the VH domain and 2FB4 (FITC, MUC1, CT) for the VL domain. Tags were removed before model generation. The models were built by ...

Bispecific antibodies designed with bYlok® technology achieve >95%* correct HC-LC pairing ... It involves the engineering of the native disulphide bridge, moving it from the constant domain (CH1/CL) ...